Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma

G. Asaithambi; B. R. Peters; Elisabeth Hurliman; B. P. Moran; A. S. Khan; R. A. Taylor

doi:10.1111/jcpt.12031

Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma

G. Asaithambi, B. R. Peters, Elisabeth Hurliman, B. P. Moran, A. S. Khan, R. A. Taylor

Dermatology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Summary What is known and Objective Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). Case summary A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. What is new and conclusion There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.

Original language	English (US)
Pages (from-to)	175-176
Number of pages	2
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	38
Issue number	2
DOIs	https://doi.org/10.1111/jcpt.12031
State	Published - Apr 2013

Keywords

adverse effect
adverse event
pazopanib
posterior reversible encephalopathy syndrome

Publisher link

10.1111/jcpt.12031

Find It

Find It at U of M Libraries

Cite this

@article{6abdeb75d90e4a9c9f521f9341f31015,

title = "Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma",

abstract = "Summary What is known and Objective Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). Case summary A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. What is new and conclusion There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.",

keywords = "adverse effect, adverse event, pazopanib, posterior reversible encephalopathy syndrome",

author = "G. Asaithambi and Peters, {B. R.} and Elisabeth Hurliman and Moran, {B. P.} and Khan, {A. S.} and Taylor, {R. A.}",

year = "2013",

month = apr,

doi = "10.1111/jcpt.12031",

language = "English (US)",

volume = "38",

pages = "175--176",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "0269-4727",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma

AU - Asaithambi, G.

AU - Peters, B. R.

AU - Hurliman, Elisabeth

AU - Moran, B. P.

AU - Khan, A. S.

AU - Taylor, R. A.

PY - 2013/4

Y1 - 2013/4

N2 - Summary What is known and Objective Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). Case summary A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. What is new and conclusion There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.

AB - Summary What is known and Objective Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). Case summary A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. What is new and conclusion There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.

KW - adverse effect

KW - adverse event

KW - pazopanib

KW - posterior reversible encephalopathy syndrome

UR - http://www.scopus.com/inward/record.url?scp=84874989131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874989131&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12031

DO - 10.1111/jcpt.12031

M3 - Article

C2 - 23210935

AN - SCOPUS:84874989131

SN - 0269-4727

VL - 38

SP - 175

EP - 176

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

IS - 2

ER -

Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma

Abstract

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this